Two Sigma Advisers
BBIO icon

Two Sigma Advisers’s BridgeBio Pharma BBIO Stock Holding History

Two Sigma Advisers’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,401,035
Closed -$107M – 243
2025
Q4 		$107M Sell
1,401,035
-261,720
-16% -$17.2M 0.21% 112
2025
Q3 		$86.4M Sell
1,662,755
-21,300
-1% -$1.04M 0.17% 128
2025
Q2 		$72.7M Buy
1,684,055
+1,410,900
+517% +$51.3M 0.15% 138
2025
Q1 		$9.44M Buy
+273,155
New +$9.21M 0.02% 552
2024
Q4 		– Sell
-40,855
Closed -$1.04M – 2345
2024
Q3 		$1.04M Sell
40,855
-211,965
-84% -$5.56M ﹤0.01% 1392
2024
Q2 		$6.4M Sell
252,820
-49,035
-16% -$1.34M 0.01% 678
2024
Q1 		$9.33M Sell
301,855
-59,900
-17% -$2.04M 0.02% 561
2023
Q4 		$14.6M Sell
361,755
-16,300
-4% -$490K 0.03% 406
2023
Q3 		$9.97M Sell
378,055
-17,190
-4% -$488K 0.03% 468
2023
Q2 		$6.8M Buy
395,245
+76,110
+24% +$1.15M 0.02% 633
2023
Q1 		$5.29M Buy
319,135
+77,700
+32% +$906K 0.01% 783
2022
Q4 		$1.84M Sell
241,435
-5,265
-2% -$50.4K 0.01% 1286
2022
Q3 		$2.45M Buy
246,700
+205,420
+498% +$2.13M 0.01% 1067
2022
Q2 		$375K Buy
41,280
+13,800
+50% +$115K ﹤0.01% 2048
2022
Q1 		$279K Sell
27,480
-26,455
-49% -$272K ﹤0.01% 2258
2021
Q4 		$900K Sell
53,935
-95,315
-64% -$4.03M ﹤0.01% 1612
2021
Q3 		$7M Sell
149,250
-108,000
-42% -$5.79M 0.02% 639
2021
Q2 		$15.7M Sell
257,250
-189,200
-42% -$10.8M 0.04% 400
2021
Q1 		$27.5M Buy
446,450
+320,550
+255% +$21M 0.08% 278
2020
Q4 		$8.95M Buy
+125,900
New +$6.07M 0.02% 603

Other funds holding BBIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Advisers's BBIO Position: Q1 2026 in Review

Two Sigma Advisers sold out of BridgeBio Pharma (BBIO) in Q1 2026, closing a stake of 1,401,035 shares — an estimated $107M sold.

Two Sigma Advisers first reported a position in BBIO in Q4 2020 and held it in 20 quarters. The position peaked at $107M in Q4 2025. 460 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Two Sigma Advisers reported no remaining BridgeBio Pharma position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 1,401,035 BridgeBio Pharma shares in Q1 2026, an estimated $107M.
  • Two Sigma Advisers first reported a position in BridgeBio Pharma in Q4 2020 and held it in 20 quarters.
  • Two Sigma Advisers's BridgeBio Pharma position peaked at $107M in Q4 2025.
  • 460 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.